Skip to main content
Start triage

Start triage first, then route to emergency care.

Start symptom intake Emergency vets near you

Need urgent help? Start triage first, then route to emergency care.

Start symptom intake Emergency vets near you

Meds A-Z

Cefpodoxime

Detailed information about Cefpodoxime

Official label facts Owner quick guide first Marketing clearly labeled
Talk to a Vet / Find a Vet Near You Start Symptom Intake

Veterinary professional?

Showing simplified owner view. Switch to Vet View for full technical detail.

Add to My Pet's Meds

Choose a pet, confirm current or past, and optionally add reminder notes.

Sign in to save this medication to your pet profile.

Sign in to continue

Reviewed / Updated / Sources

Reviewed: Not available

Updated: February 12, 2026, 10:44 PM UTC

Sources:

Pet Owner Quick Guide

Start here first for the simple next-step summary.

Used for:

For the treatment of skin infections (wounds and abscesses) caused by susceptible strains of Staphylococcus pseudintermedius , S. aureus , Streptococcus canis (group G, beta-hemolytic), Escherichia coli , Pasteurella mul...

What to watch for:

  • wobbly/unsteady walking (1 reports)
  • Loss of appetite (1 reports)
  • Ketosis (1 reports)

When to call the vet:

  • Repeated vomiting or diarrhea.
  • Severe lethargy (hard to wake, very low energy).
  • Collapse or fainting.
  • Trouble breathing.
  • Facial swelling or hives.
  • Blood in vomit or stool.

Regulatory restrictions are shown in Vet View.

What to ask your vet today:

  • Is this medicine the right fit for my pet’s current symptoms?
  • Which warning signs mean I should call back right away?
  • How should I handle missed doses or refusal to take the medicine?
Safety & side effects

What to watch:

  • wobbly/unsteady walking
  • Loss of appetite
  • Ketosis

Most reported reactions:

  • Unsteady walking (ataxia) (1 reports)
  • Loss of appetite (1 reports)
  • Ketosis (1 reports)

When to call your vet:

  • Repeated vomiting or diarrhea.
  • Severe lethargy (hard to wake, very low energy).
  • Collapse or fainting.
  • Trouble breathing.
Talk to a Vet / Find a Vet Near You Start Symptom Intake

Data freshness: source data appears current.

Latest refresh: Mar 21, 2026, 10:01 a.m.

Data freshness
  • Medication catalog: Source Roxee | Refreshed Feb 12, 2026, 10:44 PM UTC
  • Animal Drugs @ FDA: Source FDA | Refreshed Mar 21, 2026, 10:00 AM UTC
    Applications/products are imported from FDA export data.
  • Animal Drugs @ FDA previews: Source FDA | Refreshed Feb 9, 2026, 3:05 AM UTC
    Label highlights/doc links are fetched from FDA preview endpoints.
  • Animal Drug Product Listing Directory (NDC): Source FDA | Refreshed Mar 21, 2026, 10:01 AM UTC
    Package/product NDCs from FDA’s electronic listing directory (XLS).
  • openFDA reaction terms: Source FDA openFDA | Refreshed Mar 15, 2026, 10:05 AM UTC
  • openFDA case summaries: Source FDA openFDA | Refreshed Feb 9, 2026, 3:22 AM UTC
Image coming soon
Cefpodoxime

Cefpodoxime

Drug type: Generic ingredient • Branded profile • FDA branded products available

Species: Both

Manufacturer: Not available (source)

Quick Facts

Official label facts first, then secondary summaries. Marketing content is separated below.

Species: Both
Manufacturer: Not available
Form: Tablet, Tablet and Chewable Tablet
Identifiers:
ANADA: 200543 ANADA: 200815 NADA: 141232 NDC Package: 11695-7040-1 NDC Package: 11695-7040-2 NDC Package: 11695-7041-1 NDC Package: 11695-7041-2 NDC Package: 17033-431-10 NDC Package: 17033-432-10 NDC Package: 54771-5228-1 NDC Package: 54771-5228-2 NDC Package: 54771-5229-1 NDC Package: 54771-5229-2 NDC Package: 73309-025-01 NDC Package: 73309-025-02 NDC Package: 73309-025-03 NDC Package: 73377-069-01 NDC Package: 73377-069-02 NDC Package: 73377-069-03 NDC Package: 86101-033-71
Source metadata:

Warnings / Contraindications

Federal law restricts this drug to use by or on the order of a licensed veterinarian. Federal law restricts this drug to use by or on the order of a licensed veterinarian

  • High: Federal law restricts this drug to use by or on the order of a licensed veterinarian. Federal law restricts this drug to use by or on the order of a licensed veterinarian
Source metadata:

Adverse Reactions

Snapshot first, detailed rows second. This section summarizes signal data and is not a diagnosis.

Tap or hover a reaction to see what it means in plain language.

Tracked signals
32
Reported cases
32
Serious reports
27
Species represented
2
Grouped by Body System
Digestive (2) · Loss of appetite, Diarrhea Skin & allergy (4) · Joint swelling, Hair loss NOS, Facial swelling (possible allergy) Neurologic (2) · Unsteady walking (ataxia), Head tilt - neurological disorder Behavior (1) · Behavioral disorder (unspecified) Effectiveness (1) · Lack of efficacy - NOS Other (22) · Ketosis, Joint pain, Increased sweating
Most Reported Reactions
Reaction Body system Cases Species Serious cases
Neurologic 1 Dog 1
Digestive 1 Cat 1
Other 1 Cat 1
Skin & allergy 1 Cat 1
Other 1 Cat 1
Other 1 Cat 1
Other 1 Cat 1
Other 1 Dog 1

Species coverage: Cat (20) Dog (12)

View detailed reaction table
Reaction Body system Species Seriousness Frequency Reports
Neurologic Dog Serious - 1
Digestive Cat Serious - 1
Effectiveness Dog Non-serious - 1
Other Cat Serious - 1
Skin & allergy Cat Serious - 1
Other Cat Serious - 1
Other Cat Serious - 1
Other Dog Non-serious - 1
Other Cat Serious - 1
Other Dog Serious - 1
Other Cat Serious - 1
Neurologic Dog Serious - 1
Skin & allergy Cat Serious - 1
Other Cat Serious - 1
Other Cat Serious - 1
Skin & allergy Dog Serious - 1
Other Cat Serious - 1
Other Cat Serious - 1
Other Cat Serious - 1
Other Cat Serious - 1
Other Cat Serious - 1
Digestive Dog Serious - 1
Other Cat Serious - 1
Other Dog Serious - 1
Other Dog Serious - 1
Other Dog Non-serious - 1
Behavior Dog Serious - 1
Other Cat Serious - 1
Other Cat Non-serious - 1
Skin & allergy Cat Non-serious - 1
Other Dog Serious - 1
Other Cat Serious - 1
Source metadata:

Documents

Owner handouts and official technical documents are grouped for faster access.

Owner handouts (0)
  • No owner handouts linked yet.
Official label / PI (0)
  • No official label or package insert links yet.
SPL (3)
  • Cefpodoxime Proxetil Tablets · SPL
    https://animaldrugsatfda.fda.gov/adafda/app/search/public/spl/file/17507/Cefpodoxime%20Proxetil%20Tablets
  • Cefpodoxime Proxetil Tablets · SPL
    https://animaldrugsatfda.fda.gov/adafda/app/search/public/spl/file/2217/Cefpodoxime%20Proxetil%20Tablets
  • Simplicef® · SPL
    https://animaldrugsatfda.fda.gov/adafda/app/search/public/spl/file/269/Simplicef%C2%AE
FOI (4)
  • FOI Summary oA 200-815 Approved July 8, 2025.pdf · FOI
    https://animaldrugsatfda.fda.gov/adafda/app/search/public/document/downloadFoi/17208
  • UCM338192.pdf · FOI
    https://animaldrugsatfda.fda.gov/adafda/app/search/public/document/downloadFoi/1230
  • UCM433791.pdf · FOI
    https://animaldrugsatfda.fda.gov/adafda/app/search/public/document/downloadFoi/772
  • ucm118043.pdf · FOI
    https://animaldrugsatfda.fda.gov/adafda/app/search/public/document/downloadFoi/771
Source metadata:
Veterinary reference (advanced)

Canonical medication sections are above. This legacy block remains available for deeper cross-reference without cluttering the primary workflow.

At a Glance

Quick facts and links to official labeling and safety signals.

Data freshness
  • Medication catalog: Source Roxee | Refreshed Feb 12, 2026, 10:44 PM UTC
  • Animal Drugs @ FDA: Source FDA | Refreshed Mar 21, 2026, 10:00 AM UTC
    Applications/products are imported from FDA export data.
  • Animal Drugs @ FDA previews: Source FDA | Refreshed Feb 9, 2026, 3:05 AM UTC
    Label highlights/doc links are fetched from FDA preview endpoints.
  • Animal Drug Product Listing Directory (NDC): Source FDA | Refreshed Mar 21, 2026, 10:01 AM UTC
    Package/product NDCs from FDA’s electronic listing directory (XLS).
  • openFDA reaction terms: Source FDA openFDA | Refreshed Mar 15, 2026, 10:05 AM UTC
  • openFDA case summaries: Source FDA openFDA | Refreshed Feb 9, 2026, 3:22 AM UTC
Official (FDA)
Identity: Generic ingredient • FDA branded products available
Official FDA brands: Cefpodoxime Proxetil Tablets Simplicef®
Case-reported brands (openFDA): MSK
Catalog species: Both • FDA-labeled species: Dog
Rx/OTC: RX
Form/route: Tablet, Tablet and Chewable Tablet • Oral
Applications: ANADA 200-815 • ANADA 200-543 • NADA 141-232
Documents: 4 (FOI: 4) • SPL: 3 • Label highlights • Official documents
Safety (openFDA)
Top reactions: Dog 25 • Cat 13 • View
Case summaries: 10 (showing 8) • View
openFDA reports are unverified and do not prove causation.
Explore
Related conditions: Abscesses (cat bite abscess)
Linked using: Fda_Label (0.95)
Diagnosis Codes

Diagnosis-code mappings are not available for this medication yet.

Counseling and Monitoring Highlights

Global Pet owner/Vet mode is controlled in the header. This section avoids duplicate in-page persona tabs.

Owner-facing counseling points
  • Federal law restricts this drug to use by or on the order of a licensed veterinarian. Federal law restricts this drug to use by or on the order of a licensed veterinarian (Contraindication, High)
Top reaction signals
Unsteady walking (ataxia) (1) Loss of appetite (1) Ketosis (1) Joint swelling (1) Joint pain (1) Increased sweating (1) Hyperglycaemia (1) Hind limb paresis (1)

Identifiers & Packages

Normalized identifiers (NDC/NADA/ANADA) and package metadata from regulator listings.

Identifiers
ANADA: 200543 ANADA: 200815 NADA: 141232 NDC Package: 11695-7040-1 NDC Package: 11695-7040-2 NDC Package: 11695-7041-1 NDC Package: 11695-7041-2 NDC Package: 17033-431-10 NDC Package: 17033-432-10 NDC Package: 54771-5228-1 NDC Package: 54771-5228-2 NDC Package: 54771-5229-1 NDC Package: 54771-5229-2 NDC Package: 73309-025-01 NDC Package: 73309-025-02 NDC Package: 73309-025-03 NDC Package: 73377-069-01 NDC Package: 73377-069-02 NDC Package: 73377-069-03 NDC Package: 86101-033-71 NDC Package: 86101-033-76 NDC Package: 86101-034-71 NDC Package: 86101-034-76 NDC Package: 86136-134-36
Package NDC Product NDC Form / Route Status
11695-7040-1 11695 -
11695-7040-2 11695 -
11695-7041-1 11695 -
11695-7041-2 11695 -
17033-431-10 17033 -
17033-432-10 17033 -
54771-5228-1 54771 -
54771-5228-2 54771 -
54771-5229-1 54771 -
54771-5229-2 54771 -
73309-025-01 73309 -
73309-025-02 73309 -
73309-025-03 73309 -
73377-069-01 73377 -
73377-069-02 73377 -
73377-069-03 73377 -
86101-033-71 86101 -
86101-033-76 86101 -
86101-034-71 86101 -
86101-034-76 86101 -

Enriched Documents

Documents are tiered by source trust: Official, Clinical, Manufacturer, Marketing.

  • FOI Summary oA 200-815 Approved July 8, 2025.pdf • FOI summary • Official • July 31, 2025
    FDA FOI summary for application 200815
  • UCM338192.pdf • FOI summary • Official • March 16, 2019
    FDA FOI summary for application 200543
  • ucm118043.pdf • FOI summary • Official • March 15, 2019
    FDA FOI summary for application 141232
  • UCM433791.pdf • FOI summary • Official • March 15, 2019
    FDA FOI summary for application 141232

Data Sources & Change Log

Every non-trivial field is expected to include provenance and update timestamps.

Official 7 Clinical 0 Manufacturer 0 Marketing 0
Current Field Facts
  • contraindications: Federal law restricts this drug to use by or on the order of a licensed veterinarian. Federal law restricts this drug to use by or on the order of a licensed v… (Official, 2026-02-12)
  • side_effects: Top reported reactions (openFDA): Vomiting, Lack of efficacy - NOS, Lethargy (see also Central nervous system depression in 'Neurological'), Diarrhoea, Letharg… (Official, 2026-02-12)
  • usage: For the treatment of skin infections (wounds and abscesses) caused by susceptible strains of Staphylococcus pseudintermedius , Staphylococcus aureus , Streptoc… (Official, 2026-02-12)
Recent Revisions
  • side_effects updated 2026-02-12 22:44 by etl_backfill • Backfilled from existing medication fields
  • contraindications updated 2026-02-12 22:44 by etl_backfill • Backfilled from existing medication fields
  • usage updated 2026-02-12 22:44 by etl_backfill • Backfilled from existing medication fields

FDA Products & Applications (Animal Drugs @ FDA)

Official sponsor/proprietary-name/application-status records linked by active ingredient.

Product Sponsor Application Status Published
Cefpodoxime Proxetil Tablets
RX
Cefpodoxime proxetil
Tablet • Oral
Label highlights
Official documents
Felix Pharmaceuticals Pvt. Ltd. ANADA 200-815 Approved Jul 31, 2025
Cefpodoxime Proxetil Tablets
RX
Cefpodoxime proxetil
Tablet • Oral
Label highlights
Official documents
Dechra Veterinary Products LLC ANADA 200-543 Approved Mar 16, 2019
Simplicef®
RX
Cefpodoxime proxetil
Tablet and Chewable Tablet • Oral
Label highlights
Official documents
Zoetis Inc. NADA 141-232 Approved Mar 15, 2019

Data source: FDA Animal Drugs @ FDA (public search export).

What It's For (FDA Label Highlights)

Extracted from FDA Animal Drugs @ FDA product labeling. Always confirm details with your veterinarian.

Composition / specifications
100 mg and 200 mg
Dogs
Indication

For the treatment of skin infections (wounds and abscesses) caused by susceptible strains of Staphylococcus pseudintermedius, S. aureus, Streptococcus canis (group G, beta-hemolytic), Escherichia coli, Pasteurella multocida, and Proteus mirabilis.

Dosage

5 to 10 mg per kilogram (2.3 to 4.5 mg per pound) body weight daily for 5 to 7 days, or for 2 to 3 days beyond the cessation of clinical signs, up to a maximum of 28 days.

Limitations

FDA page: Open in Animal Drugs @ FDA

Species: Dog, No Use Class Stated Or Implied
Composition / specifications
100 mg, 200 mg
Label highlights
Indication

For the treatment of skin infections (wounds and abscesses) in dogs caused by susceptible strains of Staphylococcus intermedius, Staphylococcus aureus, Streptococcus canis (group G, ß hemolytic), Escherichia coli, Pasteurella multocida, and Proteus mirabilis

Dosage
5-10 mg/kg (2.3-4.5 mg/lb) body weight once a day for 5-7 days or 2-3 days beyond the cessation of clinical signs, up to a maximum of 28 days. Treatment of acute infections should not be continued for more than 3-4 days if no response to therapy is seen
Limitations
Federal law restricts this drug to use by or on the order of a licensed veterinarian

FDA page: Open in Animal Drugs @ FDA

Species: Dog, No Use Class Stated Or Implied
Dogs
Indication

For the treatment of skin infections (wounds and abscesses) caused by susceptible strains of Staphylococcus pseudintermedius, Staphylococcus aureus, Streptococcus canis (group G, ß hemolytic), Escherichia coli, Pasteurella multocida, and Proteus mirabilis.

Dosage

5 to 10 milligram per kilogram (2.3 to 4.5 milligram per pound) body weight daily for 5 to 7 days, or for 2 to 3 days beyond the cessation of clinical signs, up to a maximum of 28 days.

Limitations
Federal law restricts this drug to use by or on the order of a licensed veterinarian.

FDA page: Open in Animal Drugs @ FDA

Official Documents (FDA)

Direct links to FDA-hosted PDFs and SPL packages (when available).

Documents
  • Summary

    For the treatment of skin infections (wounds and abscesses) in dogs caused by susceptible strains of Staphylococcus pseudintermedius, Staphylococcus aureus, Streptococcus canis (group G, β hemolytic), Escherichia coli, Pasteurella multocida, and Proteus mirabilis.

SPL Packages

FDA page: Open in Animal Drugs @ FDA

Documents
  • Summary
    For the treatment of skin infections (wounds and abscesses) caused by susceptible strains of Staphylococcus intermedius, Staphylococcus aureus, Streptococcus canis (group G, ß hemolytic), Escherichia coli, Pasteurella multocida, and Proteus mirabilis.
SPL Packages

FDA page: Open in Animal Drugs @ FDA

Documents
  • Summary
    This supplement provides for the addition of a flavored, chewable tablet.
  • Summary
    For the treatment of skin infections (wounds and abscesses) caused by susceptible strains of Staphylococcus intermedius, Staphylococcus aureus, Streptococcus canis (group G, ß hemolytic), Escherichia coli, Pasteurella multocida, and Proteus mirabilis.
SPL Packages

FDA page: Open in Animal Drugs @ FDA

Usage

For the treatment of skin infections (wounds and abscesses) caused by susceptible strains of Staphylococcus pseudintermedius , Staphylococcus aureus , Streptococcus canis (group G, ß hemolytic), Escherichia coli , Pasteurella multocida , and Proteus mirabilis . For the treatment of skin infections (wounds and abscesses) in dogs caused by susceptible strains of Staphylococcus intermedius , Staphylococcus aureus , Streptococcus canis (group G, ß hemolytic), Escherichia coli , Pasteurella multocida , and Proteus mirabilis For the treatment of skin infections (wounds and abscesses) caused by susceptible strains of Staphylococcus pseudintermedius , S. aureus , Streptococcus canis (group G, beta-hemolytic), Escherichia coli , Pasteurella multocida , and Proteus mirabilis .

Source: FDA Animal Drugs @ FDA • Reference

Contraindications

Federal law restricts this drug to use by or on the order of a licensed veterinarian. Federal law restricts this drug to use by or on the order of a licensed veterinarian

Top Reported Reactions (openFDA)

De-duplicated reaction terms grouped by body system from FDA openFDA reports (not verified; does not prove causation).

Digestive
Loss of appetite (1) • Cat Diarrhea (1) • Dog

Showing top 5 for Digestive.

Skin & allergy
Joint swelling (1) • Cat Hair loss NOS (1) • Cat Facial swelling (possible allergy) (1) • Dog Application site hair loss (1) • Cat

Showing top 5 for Skin & allergy.

Neurologic
Unsteady walking (1) • Dog Head tilt - neurological disorder (1) • Dog

Showing top 5 for Neurologic.

Behavior
Behavioral disorder (1) • Dog

Showing top 5 for Behavior.

Effectiveness
Lack of efficacy - NOS (1) • Dog

Showing top 5 for Effectiveness.

Other
Ketosis (1) • Cat Joint pain (1) • Cat Increased sweating (1) • Cat Hypothyroidism (1) • Dog Hyperglycaemia (1) • Cat
Show more (17)
Hind limb paresis (1) • Dog Hepatic lipidosis (1) • Cat Generalised weakness (1) • Cat Fever (1) • Cat Elevated total bilirubin (1) • Cat Elevated serum alkaline phosphatase (1) • Cat Elevated gamma-glutamyl transferase (1) • Cat Elevated blood urea nitrogen (1) • Cat Elevated alanine aminotransferase (1) • Cat Decreased bowel movements (1) • Cat Deafness (1) • Dog Cognitive disorder NOS (1) • Dog Cellulitis (1) • Dog Arthropathy NOS (1) • Cat Application site irritation (1) • Cat Application site discharge NOS (1) • Dog Abnormal radiograph finding (1) • Cat

Showing top 5 for Other.

Data source: FDA openFDA Animal & Veterinary adverse event reports.

Adverse Event Case Summaries (openFDA)

These are individual FDA adverse event reports. They are unverified and do not prove the medication caused the reaction.

Dog, Terrier - Bull - American Pit, Male, 14 year, 24.494 kilogram • Drug: MSK, Unassigned, Unknown • Reactions: Stiff gait, Cognitive disorder NOS, Malaise, Vomiting, Diarrhea… • Outcome: Ongoing

  • Report ID: USA-USFDACVM-2025-US-055236
  • Serious AE: Yes
  • Treated For AE: Yes
  • Sex: Male
  • Age: 14.00 Year
  • Weight: 24.494 Kilogram
  • Case-reported brand: MSK
  • Case-reported manufacturer: MSK
  • Route: Unknown
  • Form: Unassigned
Reactions Reported:
Stiff gait Cognitive disorder NOS Malaise Vomiting Diarrhea Hind limb paresis Unable to stand Unable to walk Proprioception deficit Tremors Fever Unsteady walking (ataxia) Behavioral disorder (unspecified)
Outcomes: Ongoing

Dog, Mastiff (unspecified), Male, 5.5 year, 90.26 kilogram • Drug: MSK, Unknown • Reactions: Regenerative anaemia, Tiredness (lethargy), Localised oedema, Uncomfortable, Lack of efficacy - NOS… • Outcome: Ongoing

  • Report ID: USA-USFDACVM-2025-US-054417
  • Serious AE: No
  • Treated For AE: Yes
  • Sex: Male
  • Age: 5.50 Year
  • Weight: 90.260 Kilogram
  • Case-reported brand: MSK
  • Case-reported manufacturer: MSK
  • Route: Unknown
Reactions Reported:
Regenerative anaemia Tiredness (lethargy) Localised oedema Uncomfortable Lack of efficacy - NOS Cellulitis Low thyroxine Swelling NOS Hypothyroidism Lick granuloma
Outcomes: Ongoing

Dog, Terrier - Boston, Female, 13 year, 9.979 kilogram • Drug: MSK, Unassigned, Unknown • Reactions: Facial swelling (possible allergy), Head tilt - neurological disorder, Staggering • Outcome: Ongoing

  • Report ID: USA-USFDACVM-2025-US-055030
  • Serious AE: Yes
  • Treated For AE: Yes
  • Sex: Female
  • Age: 13.00 Year
  • Weight: 9.979 Kilogram
  • Case-reported brand: MSK
  • Case-reported manufacturer: MSK
  • Route: Unknown
  • Form: Unassigned
Reactions Reported:
Facial swelling (possible allergy) Head tilt - neurological disorder Staggering
Outcomes: Ongoing

Dog, Terrier - Fox Wire, Male, 10.8 year, 9.68 kilogram • Drug: MSK, Oral, Dose: 100 Milligram per animal, Frequency: 24 per hour • Reactions: Deafness, Tympanic rupture, Application site discharge NOS • Outcome: Outcome Unknown

  • Report ID: USA-USFDACVM-2025-US-053873
  • Serious AE: Yes
  • Treated For AE: No
  • Sex: Male
  • Age: 10.80 Year
  • Weight: 9.680 Kilogram
  • Case-reported brand: MSK
  • Case-reported manufacturer: MSK
  • Route: Oral
  • Dose: 100 Milligram per animal
  • Frequency: 24 per hour
Reactions Reported:
Deafness Tympanic rupture Application site discharge NOS
Outcomes: Outcome Unknown

Dog, Shepherd Dog - German, Male, 4.9 year, 35.11 kilogram • Drug: MSK, Unassigned, Oral • Reactions: Lack of efficacy - NOS • Outcome: Ongoing

  • Report ID: USA-USFDACVM-2025-US-055356
  • Serious AE: Yes
  • Treated For AE: Yes
  • Sex: Male
  • Age: 4.90 Year
  • Weight: 35.110 Kilogram
  • Case-reported brand: MSK
  • Case-reported manufacturer: MSK
  • Route: Oral
  • Form: Unassigned
Reactions Reported:
Lack of efficacy - NOS
Outcomes: Ongoing

Cat, Domestic Shorthair, Male, 6 year, 5.443 kilogram • Drug: MSK, Oral • Reactions: Loss of appetite, Ketosis, Elevated alanine aminotransferase, Elevated blood urea nitrogen, Elevated serum alkaline phosphatase… • Outcome: Outcome Unknown

  • Report ID: USA-USFDACVM-2025-US-052288
  • Serious AE: Yes
  • Treated For AE: Yes
  • Sex: Male
  • Age: 6.00 Year
  • Weight: 5.443 Kilogram
  • Case-reported brand: MSK
  • Case-reported manufacturer: MSK
  • Route: Oral
Reactions Reported:
Loss of appetite Ketosis Elevated alanine aminotransferase Elevated blood urea nitrogen Elevated serum alkaline phosphatase Elevated total bilirubin Elevated gamma-glutamyl transferase Hepatic lipidosis
Outcomes: Outcome Unknown

Cat, Domestic Mediumhair, Male, 14 year, 6.65 kilogram • Drug: MSK, Tablet, Oral, Dose: 50 Milligram per animal, Frequency: 1 per day • Reactions: Hair loss NOS, Joint swelling, Vocalisation, Joint pain, Abnormal radiograph finding… • Outcome: Ongoing

  • Report ID: USA-USFDACVM-2025-US-013835
  • Serious AE: Yes
  • Treated For AE: Yes
  • Sex: Male
  • Age: 14.00 Year
  • Weight: 6.650 Kilogram
  • Case-reported brand: MSK
  • Case-reported manufacturer: MSK
  • Route: Oral
  • Form: Tablet
  • Dose: 50 Milligram per animal
  • Frequency: 1 per day
Reactions Reported:
Hair loss NOS Joint swelling Vocalisation Joint pain Abnormal radiograph finding Arthropathy NOS
Outcomes: Ongoing

Cat, Domestic Shorthair, Female, 10 year, 6.976 kilogram • Drug: MSK, Oral • Reactions: Application site irritation, Application site hair loss • Outcome: Ongoing

  • Report ID: USA-USFDACVM-2024-US-063739
  • Serious AE: No
  • Treated For AE: Yes
  • Sex: Female
  • Age: 10.00 Year
  • Weight: 6.976 Kilogram
  • Case-reported brand: MSK
  • Case-reported manufacturer: MSK
  • Route: Oral
Reactions Reported:
Application site irritation Application site hair loss
Outcomes: Ongoing

Data source: FDA openFDA Animal & Veterinary adverse event reports.

Overdose Information

No approved overdose-management text is linked yet. If overdose is suspected, contact a veterinarian or emergency clinic immediately.

Storage & Handling

No approved storage guidance is linked yet for this ingredient. Use manufacturer packaging and veterinary guidance for handling/storage.

Share Your Thoughts

Let others know your experience or advice regarding this medication.

This medication has not been reviewed by a veterinarian yet.